File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Decline of HBV covalently closed circular DNA during telbivudine and lamivudine therapy

TitleDecline of HBV covalently closed circular DNA during telbivudine and lamivudine therapy
Authors
Issue Date2008
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The 43rd Annual Meeting of the European Association for the Study of the Liver (The International Liver Congress™ 2008), Milan, Italy, 23–27 April 2008. In Journal of Hepatology, 2008, v. 48 suppl. 2, p. S375, abstarct no. 1002 How to Cite?
AbstractBACKGROUND AND AIMS: Telbivudine has been shown to have a higher rate of reduction of serum hepatitis B virus (HBV) DNA, normalization of transaminase and histologic improvement than lamivudine in both HBeAg-positive and HBeAg-negative patients [1]. However, the effect of telbivudine therapy on the reduction of covalently closed circular DNA (cccDNA) levels in liver has not been investigated. This study aimed to compare the effect of one year of telbivudine vs. lamivudine therapy on cccDNA levels. PATIENTS AND METHODS: Thirty-eight patients (25 HBeAg-positive and 13 anti-HBe-negative) on 600 mg daily telbivudine and 32 patients (24 HBeAg-positive and 8 anti-HBe-positive) on 100 mg daily lamivudine were recruited These patients were enrolled in the Globe phase 3 trial at our center in Hong Kong. Liver biopsies were taken at baseline and week 52 of therapy. Serum HBV DNA was quantitated by the COBAS Amplicor Monitor Test. Intrahepatic HBV DNA and cccDNA were measured by a previously validated real-time PCR assay [2]. RESULTS: Patients treated with telbivudine had a greater median reduction of serum HBV DNA at week 52 than those treated with lamivudine (6.0 vs. 4.1 log10 copies/mL, respectively, P = 0.041). At week 52, median reduction of intrahepatic total HBV DNA for telbivudine and lamivudine patients were 1.2 and 1.3 log10 copies/cell, respectively (P = 0.973) and for cccDNA were 0.11 and −0.07 log10 copies/cell, respectively (P = 0.217). CONCLUSIONS: There was no significant difference between treatments in the magnitude of the observed reduction in intrahepatic HBV DNA and cccDNA levels even though telbivudine was more potent than lamivudine in the suppression of serum HBV DNA replication. This extends previous findings with no difference observed in the reduction of intrahepatic HBV DNA and cccDNA levels when comparing entecavir vs. lamivudine treatment for 1 year. It may be possible to determine the efficacy of therapeutic treatments using samples obtained after longer treatments. References [1] Lai et al, N Engl J Med (2007) 357: 2576−88. [2] Wong, Yuen, Ngai, Fung, Lai, Antivir Ther (2006) 11: 909–916.
Persistent Identifierhttp://hdl.handle.net/10722/102762
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570

 

DC FieldValueLanguage
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorYuen, RMFen_HK
dc.contributor.authorFung, JYYen_HK
dc.contributor.authorWu, CHen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-25T20:43:48Z-
dc.date.available2010-09-25T20:43:48Z-
dc.date.issued2008en_HK
dc.identifier.citationThe 43rd Annual Meeting of the European Association for the Study of the Liver (The International Liver Congress™ 2008), Milan, Italy, 23–27 April 2008. In Journal of Hepatology, 2008, v. 48 suppl. 2, p. S375, abstarct no. 1002en_HK
dc.identifier.issn0168-8278en_HK
dc.identifier.urihttp://hdl.handle.net/10722/102762-
dc.description.abstractBACKGROUND AND AIMS: Telbivudine has been shown to have a higher rate of reduction of serum hepatitis B virus (HBV) DNA, normalization of transaminase and histologic improvement than lamivudine in both HBeAg-positive and HBeAg-negative patients [1]. However, the effect of telbivudine therapy on the reduction of covalently closed circular DNA (cccDNA) levels in liver has not been investigated. This study aimed to compare the effect of one year of telbivudine vs. lamivudine therapy on cccDNA levels. PATIENTS AND METHODS: Thirty-eight patients (25 HBeAg-positive and 13 anti-HBe-negative) on 600 mg daily telbivudine and 32 patients (24 HBeAg-positive and 8 anti-HBe-positive) on 100 mg daily lamivudine were recruited These patients were enrolled in the Globe phase 3 trial at our center in Hong Kong. Liver biopsies were taken at baseline and week 52 of therapy. Serum HBV DNA was quantitated by the COBAS Amplicor Monitor Test. Intrahepatic HBV DNA and cccDNA were measured by a previously validated real-time PCR assay [2]. RESULTS: Patients treated with telbivudine had a greater median reduction of serum HBV DNA at week 52 than those treated with lamivudine (6.0 vs. 4.1 log10 copies/mL, respectively, P = 0.041). At week 52, median reduction of intrahepatic total HBV DNA for telbivudine and lamivudine patients were 1.2 and 1.3 log10 copies/cell, respectively (P = 0.973) and for cccDNA were 0.11 and −0.07 log10 copies/cell, respectively (P = 0.217). CONCLUSIONS: There was no significant difference between treatments in the magnitude of the observed reduction in intrahepatic HBV DNA and cccDNA levels even though telbivudine was more potent than lamivudine in the suppression of serum HBV DNA replication. This extends previous findings with no difference observed in the reduction of intrahepatic HBV DNA and cccDNA levels when comparing entecavir vs. lamivudine treatment for 1 year. It may be possible to determine the efficacy of therapeutic treatments using samples obtained after longer treatments. References [1] Lai et al, N Engl J Med (2007) 357: 2576−88. [2] Wong, Yuen, Ngai, Fung, Lai, Antivir Ther (2006) 11: 909–916.-
dc.languageengen_HK
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhepen_HK
dc.relation.ispartofJournal of Hepatologyen_HK
dc.rightsJournal of Hepatology. Copyright © Elsevier BV.en_HK
dc.titleDecline of HBV covalently closed circular DNA during telbivudine and lamivudine therapyen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0168-8278&volume=48 &issue=Suppl 2&spage=S375&epage=&date=2008&atitle=Decline+of+HBV+covalently+closed+circular+DNA+during+telbivudine+and+lamivudine+therapyen_HK
dc.identifier.emailWong, DKH: danywong@hku.hken_HK
dc.identifier.emailYuen, RMF: mfyuen@hkucc.hku.hken_HK
dc.identifier.emailFung, JYY: jfung@sicklehut.comen_HK
dc.identifier.emailWu, CH: rchwu@HKUCC.hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityYuen, RMF=rp00479en_HK
dc.identifier.authorityFung, JYY=rp00518en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0168-8278(08)61004-1-
dc.identifier.hkuros152612en_HK
dc.identifier.volume48en_HK
dc.identifier.issuesuppl. 2en_HK
dc.identifier.spageS375, abstarct no. 1002en_HK
dc.identifier.epageS375, abstarct no. 1002-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats